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Abstract
Background: When this trial was initiated, the combined measles, mumps and rubella (MMR) vaccine was licensed for
subcutaneous administration in all European countries and for intramuscular administration in some countries, whereas varicella
vaccine was licensed only for subcutaneous administration. This study evaluated the intramuscular administration of an MMR
vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) compared with the subcutaneous route.
Methods: An open-label randomised trial was performed in France and Germany. Healthy children, aged 12 to18 months,
received single injections of M-M-RvaxPro and VARIVAX concomitantly at separate injection sites. Both vaccines were
administered either intramuscularly (IM group, n = 374) or subcutaneously (SC group, n = 378). Immunogenicity was assessed
before vaccination and 42 days after vaccination. Injection-site erythema, swelling and pain were recorded from days 0 to 4 after
vaccination. Body temperature was monitored daily between 0 and 42 days after vaccination. Other adverse events were
recorded up to 42 days after vaccination and serious adverse events until the second study visit.
Results: Antibody response rates at day 42 in the per-protocol set of children initially seronegative to measles, mumps, rubella
or varicella were similar between the IM and SC groups for all four antigens. Response rates were 94 to 96% for measles, 98%
for both mumps and rubella and 86 to 88% for varicella. For children initially seronegative to varicella, 99% achieved the
seroconversion threshold (antibody concentrations of ≥ 1.25 gpELISA units/ml). Erythema and swelling were the most frequently
reported injection-site reactions for both vaccines. Most injection-site reactions were of mild intensity or small size (≤ 2.5 cm).
There was a trend for lower rates of injection-site erythema and swelling in the IM group. The incidence and nature of systemic
adverse events were comparable for the two routes of administration, except varicella-like rashes, which were less frequent in
the IM group.
Conclusion: The immunogenicities of M-M-RvaxPro and VARIVAX administered by the intramuscular route were comparable
with those following subcutaneous administration, and the tolerability of the two vaccines was comparable regardless of
administration route. Integration of both administration routes in the current European indications for the two vaccines will
now allow physicians in Europe to choose their preferred administration route in routine clinical practice.
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Background
Although many people consider measles, mumps, rubella
and varicella to be 'minor' illnesses, they all carry the risk
of serious complications, which may lead to long-term
morbidity or death [1-4]. In addition to the distress that
these diseases and their complications may cause to
affected children and their families, the direct and societal
costs of hospitalisation and outpatient visits to manage
complications are substantial [5].
The development of vaccines against these four histori-
cally common childhood diseases has led to a significant
decline in their incidence in countries with routine paedi-
atric vaccination programmes. For example, a two-dose
vaccination schedule with the combined measles, mumps
and rubella (MMR) vaccine (M-M-R™ II, Merck & Co.,
Inc.), consisting of the measles virus more attenuated
Enders' Edmonston strain, the mumps virus Jeryl Lynn™
(level B) strain and the rubella virus Wistar RA 27/3 strain,
has led to elimination of all three diseases in Finland [6]
and a greater than 90% reduction in their incidence in
Sweden and the USA [7,8]. A live, attenuated varicella vac-
cine (VARIVAX®, Merck & Co., Inc., Oka/Merck strain) was
introduced in the USA in 1995. Following its introduc-
tion, the age-adjusted annual incidence of varicella in the
USA decreased from 2.63 cases per 1000 person-years dur-
ing 1995 to 0.92 cases per 1000 person-years during 2002,
and there was a 75% decrease in incidence among chil-
dren aged 1 to 4 years between 1992–1996 and 2002 [9].
Furthermore, age-adjusted mortality rates for varicella-
associated deaths declined by 66% from 1990–1994 to
1999–2001, with the greatest reduction (92%) seen
among children aged 1 to 4 years [10].
Despite the evidence of the reduction in incidence of mea-
sles, mumps and rubella that can be achieved by vaccina-
tion, and the fact that all member states of the World
Health Organization (WHO) Europe Region have
adopted a two-dose measles vaccination schedule, the
coverage rates for MMR vaccination in Europe, particu-
larly with respect to the second dose, are still too low to
achieve the WHO objective of eliminating all three dis-
eases in Europe by 2010 [11-13]. Furthermore, although
the USA has demonstrated the benefits of universal vacci-
nation of children aged 12 to 18 months against varicella
[14], Germany [15] and some regions of Italy and Spain
[16] are currently the only parts of Europe to recommend
universal childhood vaccination against varicella. Other
European countries have yet to fully evaluate and adopt
varicella vaccination programmes [17,18].
Worldwide, over 500 million doses of M-M-R II have been
distributed, and it has been shown to be generally well
tolerated, immunogenic and efficacious [19,20]. M-M-R II
has been proven to be effective in preventing the develop-
ment of measles (91% to 100% efficacy) [21,22], mumps
(75% to 96% efficacy) [23,24] and rubella (93% to 100%
efficacy) [25,26].
M-M-RvaxPro®, a new version of M-M-R II that contains
the same components, obtained its marketing authorisa-
tion in Europe in May 2006. The only difference between
M-M-R II and M-M-RvaxPro resides in the replacement of
human serum albumin in M-M-R II with recombinant
human albumin during the manufacturing of measles,
mumps and rubella viral bulks. The immunogenicity and
safety profiles of M-M-RvaxPro have been shown to be
comparable with those of M-M-R II [27].
VARIVAX has also been shown to be immunogenic, effec-
tive and well tolerated. The results from a study on 1164
healthy children concluded that an antibody concentra-
tion of ≥ 5 glycoprotein (gp) enzyme-linked immuno-
sorbent assay (ELISA) units/ml could be regarded as an
approximate correlate of protection for individual vac-
cinees [28]. Seroconversion rates (increase above the
threshold of ≥ 1.25 gpELISA units/ml) after administra-
tion of a single dose of VARIVAX range from 94% to 96%
[29,30]. In clinical practice, the efficacy of VARIVAX is
approximately 85% against all forms of varicella and
about 97% against moderately severe to severe forms [31-
33].
The opportunity to administer vaccines concomitantly
can improve compliance with paediatric vaccination regi-
mens and enhance vaccine coverage [34]. It has been dem-
onstrated previously that M-M-R II and VARIVAX,
administered subcutaneously at two separate injection
sites during the same visit to children aged between 12
months and 6 years, are generally well tolerated and
immunogenic, with protection against varicella main-
tained for up to 6 years [35].
In Europe, recommendations and preferred practices vary
with regard to the route of vaccination. At the start of the
study, the MMR vaccine from Merck was licensed for sub-
cutaneous (SC) administration in all European countries,
and in some countries for both SC and intramuscular
(IM) administration, whereas the varicella vaccine was
licensed only for SC administration. It is generally
accepted, however, that many physicians prefer to admin-
ister vaccines intramuscularly. This study was thus per-
formed to compare the immunogenicity and safety of M-
M-RvaxPro and VARIVAX when both are administered
concomitantly at separate injection sites by either the SC
or the IM route.BMC Medicine 2009, 7:16 http://www.biomedcentral.com/1741-7015/7/16
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Methods
Study design and conduct
This open-label, randomised trial was performed in
France (39 centres) and Germany (33 centres) between
January and September 2005. The study was performed in
accordance with the principles of the Declaration of Hel-
sinki and of Good Clinical Practice and was registered on
the European Communities trial registry http://
eudract.emea.europa.eu/. Approval was obtained from
the relevant competent authorities and ethics committees
(CCPPRB (Comité Consultatif pour la Protection des Per-
sonnes dans la Recherche Biomédicale) of Lyon A, France
and independent ethics committee of Rheinland Pfalz,
Mainz, Germany) before the trial began. Written
informed consent was obtained from parents or legal
guardians of all children before enrolment in the study.
Study population and vaccines
Healthy children of either sex, between 12 and 18 months
of age, were eligible for inclusion in the study. Participants
were required to have no history of vaccination for mea-
sles, mumps, rubella or varicella, and no suspected clini-
cal history or exposure in the past 30 days to these
diseases. They should also have had no history of febrile
illness (rectal temperature ≥ 38°C) within the 3 days
before enrolment, and to have no known sensitivity or
allergy to any component of the study vaccines. Children
who had received any vaccine in the 30 days before enrol-
ment were not eligible for inclusion. Children with
immune impairment or humoral and/or cellular defi-
ciency, neoplastic disease or depressed immunity, includ-
ing that resulting from long-term (≥ 14 days)
corticosteroid administration at high doses, were also not
eligible.
Group allocation was performed using balanced per-
muted blocks of randomisation of size 4. The randomisa-
tion was stratified by centre and generated by a non-study
statistician from the clinical research organisation S-Cli-
nica. The investigators called an interactive voice response
system (to avoid subject selection bias) to determine
which administration route (IM or SC) was to be used.
Infants received single concomitant doses of M-M-Rvax-
Pro and VARIVAX, either both by IM or both by SC, at sep-
arate injection sites in the upper arm. The use of
anaesthetic preparations at the injection sites was not per-
mitted. To decrease the chances of the investigators being
biased by remembering the route of administration for
the safety assessment at the second study visit (42 to 56
days after vaccination), they were instructed to record the
route of administration in the vaccination log and in the
relevant section of the case report form and then to seal
these documents in an envelope that could not be opened
until after the second visit.
M-M-RvaxPro is a lyophilised live virus vaccine manufac-
tured with recombinant human albumin for vaccination
against measles, mumps and rubella. The 50% cell-cul-
ture-infectious dose was not less than 1 × 103 for measles
(derived from attenuated Enders' Edmonston strain) and
rubella (Wistar RA 27/3 strain), and not less than 12.5 ×
103 for mumps (Jeryl Lynn [Level B] strain). VARIVAX is a
lyophilised preparation of the live Oka strain varicella
virus, with a potency of not less than 1350 plaque-form-
ing units. Both vaccines were stored at 2°C to 8°C and
reconstituted with sterile water for injections immediately
before use.
Subcutaneous and intramuscular vaccination techniques
The needles used to reconstitute the vaccines were
replaced with fresh 25-gauge 16 mm-long needles before
injection. For IM injections, the investigators were advised
to use their thumb and index finger to stretch the skin flat
over the deltoid muscle to insert the needle perpendicular
to the skin and then to inject the vaccine. For the SC injec-
tions, the investigators were advised to hold the skin and
subcutaneous tissue in the deltoid area between their
thumb and fingers thus producing a skin fold, to insert the
needle into the fold at about 45° and then inject the vac-
cine while taking care to deliver it only in the SC tissue.
Objectives
The primary objectives of the study were to assess if, in
children aged 12 to 18 months at 42 days following vacci-
nation:
￿ a single dose of M-M-RvaxPro administered by the
IM route concomitantly with VARIVAX by the same
route at separate injection sites;
￿ and/or, a single dose of VARIVAX administered by
the IM route concomitantly with M-M-RvaxPro by the
same route at separate injection sites
were, in terms of response rates, non-inferior compared
with the same vaccine administered by the SC route. Suc-
cess was defined in this study as either one or both pri-
mary objectives being reached, therefore the type 1 error
rate was adjusted using the method described in the statis-
tical methods below.
The secondary objectives of the study were to determine
the antibody concentrations to measles, mumps, rubella
and varicella at 42 days after concomitant vaccination and
to evaluate the safety profiles of the two vaccines and
routes of administration.
Assessments
For assessment of immunogenicity, a 5 ml blood sample
was taken before vaccination and at the second study visitBMC Medicine 2009, 7:16 http://www.biomedcentral.com/1741-7015/7/16
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(days 42 to 56 days after vaccination). The concentrations
of antibodies were determined by Merck Research Labora-
tories (West Point, Pennsylvania, USA) on the serum sam-
ples using ELISA for measles, mumps and rubella and a
gpELISA for varicella [36-38].
The primary immunogenicity criteria were the response
rates to measles, mumps and rubella and varicella defined
as the percentage of subjects who had been seronegative
before vaccination and who developed antibody concen-
trations of ≥ 255 mIU/ml for measles, ≥ 10 ELISA Ab units
for mumps, ≥ 10IU/ml for rubella and ≥ 5gpELISA units/
ml for varicella 42 days following vaccination. In addi-
tion, we also ascertained the seroconversion rate for vari-
cella defined as the percentage of subjects who were
seronegative before vaccination and who developed post-
vaccination antibody concentrations of ≥ 1.25gpELISA
units/ml. The secondary immunogenicity criteria were the
post-vaccination geometric mean concentrations (GMCs)
of antibodies to measles, mumps, rubella and varicella.
Parents or legal guardians were asked to record all injec-
tion-site reactions and any systemic adverse events in a
diary card from day 0 (day of vaccination) until day 42
post vaccination. Solicited injection-site reactions (ery-
thema, swelling and pain) were recorded on days 0 to 4.
Other injection-site reactions (spontaneously reported),
daily axillary temperature, measles-, rubella- or varicella-
like rashes, and mumps-like symptoms, and any other sys-
temic adverse events were recorded from days 0 to 42.
Serious adverse events were recorded from day 0 until the
final study visit. The parents or legal guardians were asked
to notify the investigator if their child developed a mea-
sles-, rubella- or varicella-like rash or mumps-like illness,
or if they experienced a serious adverse event. They were
also instructed to measure the rectal temperature if their
child's axillary temperature was ≥ 37.1°C.
Statistical analyses
The primary hypotheses were that the response rates
defined for each antigen as primary criteria for children in
the IM group would not be inferior to those for children
in the SC group for one or both vaccines. The sample size
calculation was based on these primary hypotheses. The
immunogenicity analysis was performed on a per-proto-
col set of subjects (PPS) that included all randomised chil-
dren, except those with a protocol violation that might
have interfered with the immunogenicity evaluation –
main analysis and on a full-analysis set (FAS) that
included all randomised children who received at least
one study vaccine and for whom a post-vaccination
immunogenicity evaluation was available. Only children
who were seronegative at baseline were included in the
PPS analysis for the corresponding antigen (antigen-spe-
cific PPS) whereas all subjects were included in the FAS,
regardless of their initial serostatus. The statistical analysis
for the primary endpoint was based on two-sided confi-
dence intervals (CI) around the difference in response
rates [IM – SC] for each vaccine antigen. The analysis for
the demonstration of the non-inferiority of response rates
for the IM group compared with the SC group was based
on the method proposed by Miettinen and Nurminen
[39] with stratification by region (that is, pooled data
from centres based on geographic location). In addition
we performed non-stratified analyses to verify the robust-
ness of the primary results.
The non-inferiority criterion for each antigen was
achieved if the lower limit of the CI was above – 10%. To
adjust for multiple statistical testing we used the method
proposed by Hochberg [40], which leads to different CI
limits, depending on the results of the study (95% if non-
inferiority was demonstrated for both vaccines and 97.5%
in case of failure of one vaccine).
Descriptive analyses were performed for measles, mumps,
rubella and varicella GMCs (with 95% CI). The safety
analysis was performed on all children who received at
least one of the study vaccines and for whom safety fol-
low-up data were available. The analysis was performed
according to the route actually used for vaccination. Chil-
dren with vaccination errors were excluded from the safety
analysis; however, their safety data were carefully
reviewed.
All statistical analyses were performed using SAS® software
version 8.2 (SAS Institute Inc., Cary, North Carolina,
USA).
Results
Subjects
In total, 752 children were randomised and received M-
M-RvaxPro and VARIVAX either by the intramuscular (n =
374) or subcutaneous (n = 378) route.
Overall, the mean age at vaccination was 13.7 ± 1.7
months, and there were slightly more boys (416; 55.3%)
than girls (336; 44.7%) included in the study. Children in
the two vaccination groups were comparable with respect
to age at vaccination, gender, weight and height (Table 1).
The two groups were also comparable in the percentages
of children who were seronegative at baseline for measles,
mumps, rubella and varicella (Table 1).
Immunogenicity
The composition of the antigen-specific PPS is detailed in
Table 2. In each antigen-specific PPS, the antibody
response rates at 42 days post vaccination for children ini-
tially seronegative to measles, mumps, rubella or varicella
were non-inferior in the IM compared with the SC groupsBMC Medicine 2009, 7:16 http://www.biomedcentral.com/1741-7015/7/16
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(Table 3). In both groups, response rates were 94% to
96% for measles, and 98% for mumps and rubella. For
varicella, 86% of children in the SC group and 88% in the
IM group had antibody concentrations ≥ 5gpELISA units/
ml, while 98.5% (96.6, 99.5) and 99.4% (97.9, 99.9) in
the IM and SC groups, respectively, had concentrations ≥
1.25gpELISA units/ml. The lowest lower limit for the 95%
CIs of the response rates for the four antigens was -5.28%
(for measles). The primary hypothesis that the intramus-
cular route of administration is not inferior to the subcu-
taneous route was therefore met for all antigens and thus
for both vaccines. The immunogenicity results for the FAS
were comparable with those for each PPS, and results
from the sensitivity analyses showed they were robust
(data not shown).
In each antigen-specific PPS, the GMCs at day 42 for anti-
bodies against measles, mumps, rubella and varicella in
children initially seronegative to the corresponding anti-
gen were comparable between the IM and SC groups
(Table 4). The reverse cumulative distribution curves, for
each valence, confirm the similarity of the response rates
between groups (Figure 1).
Safety
One child in the IM group was withdrawn from the study
for personal reasons and one in the SC group did not
attend the second (last) study visit; however, safety data
for both children were collected by telephone at the time
of visit 2. No child was withdrawn from the study because
of an adverse event.
One child who was randomised to the SC group but
received both vaccines by the intramuscular route was
included in the IM group for the safety analysis and two
children (one from each group) were excluded from the
safety analysis due to vaccination errors; one child
received only the diluent of M-M-RvaxPro and the other
child received M-M-RvaxPro by deep subcutaneous injec-
tion. The safety analysis was thus performed on 374 chil-
dren in the IM group and 376 children in the SC group.
Table 1: Demographic and baseline data in the randomised set.
IM Group
 N = 374
SC Group
 N = 378
Age at vaccination, months ± SD 13.8 ± 1.7 13.7 ± 1.6
Male, n (%) 206 (55.1) 210 (55.6)
Weight, kg ± SD 10.1 ± 1.2 10.2 ± 1.3
Height, cm ± SD 77.2 ± 3.6 77.4 ± 3.4
Seronegative, n (%)1
Measles (<255 mIU/ml) 364 (97.3) 371 (98.1)
Mumps (<10 ELISA Ab units/ml) 364 (97.3) 370 (97.9)
Rubella (<10 IU/ml) 335 (89.6) 324 (85.7)
Varicella (<1.25 gpELISA units/ml) 352 (94.1) 353 (93.4)
(IM group, both vaccines administered by the intramuscular route; SC 
group, both vaccines administered by the subcutaneous route).
1 It is not possible to calculate the seropositive rates directly from 
these data because of the missing values; overall 5 (0.7%) subjects 
were seropositive at baseline for measles, 11 (1.5%) for mumps, 81 
(10.8%) for rubella and 37 (4.9%) for varicella
Table 2: Composition of the antigen-specific per protocol sets (PPSs)
IM Group SC Group
Measles Mumps Rubella Varicella Measles Mumps Rubella Varicella
Randomised 374 374 374 374 378 378 378 378
Vaccinated 374 374 374 374 378 378 378 378
Analysed in PPS 349 349 321 336 363 363 318 345
Not included in PPS1 25 25 53 38 15 15 60 33
- Seropositive at baseline 3 7 32 18 2 4 49 19
- Protocol deviations2 23 19 23 20 13 11 13 143
(IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route).
1 An infant could have more than one reason for not being included in the PPS, and some deviations do not apply to all valences; for example, data 
for one valence could be missing because there was not enough serum to perform the assay.
2 Protocol deviations included: previous vaccination for measles, mumps rubella or varicella; received non-study vaccine close to inclusion; route of 
vaccination different from that allocated by randomisation; initial serostatus unknown (first blood sample not taken or missing data), post-
vaccination data missing (blood sample not taken or missing data); blood sample not taken at the right time; received only vaccine diluent.
3 Includes one subject exposed to varicella during follow-up.BMC Medicine 2009, 7:16 http://www.biomedcentral.com/1741-7015/7/16
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A total of 313 (83.7%) children in the IM group and 325
(86.4%) children in the SC group had at least one adverse
event (injection-site reaction or systemic adverse event)
within 42 days following vaccination. In both groups,
approximately half of the children experienced at least
one adverse event (injection-site reaction or systemic
adverse event) related to each vaccine: 50.8% in the IM
group and 53.7% in the SC group had an adverse event
assessed by the investigators as being related to vaccina-
tion with M-M-RvaxPro. The corresponding rates for VAR-
IVAX were 46.3% and 55.9%, respectively.
For both vaccines and both administration routes, most
injection-site reactions were of mild intensity or small size
(≤ 2.5cm). Although not formally tested, there was a trend
for lower rates for solicited injection-site reactions on days
0 to 4 in the IM group compared with the SC group (Table
5). Most solicited injection-site reactions occurred on the
day of vaccination and resolved within 1 day. The same
Table 3: Response rates to measles, mumps, rubella and varicella at 42 days post vaccination for children initially seronegative to 
measles, mumps, rubella or varicella in the antigen-specific per-protocol sets
IM Group
N = 3741
SC Group
N = 3781
Difference (%)3
IM group – SC group
[95% CI]
n2 Response rate
n (%)4
[95% CI]
n2 Response rate
n (%)4
[95% CI]
Measles (≥ 255 mIU/Ml) 349 329 (94.3)
[91.3; 96.5]
363 349 (96.1)
[93.6; 97.9]
-1.89
[-5.28; 1.29]
Mumps (≥ 10 ELISA Ab units/ml) 349 341 (97.7)
[95.5; 99.0]
363 356 (98.1)
[96.1; 99.2]
-0.33
[-2.67; 2.00]
Rubella (≥ 10 IU/ml) 321 315 (98.1)
[96.0; 99.3]
318 312 (98.1)
[95.9; 99.3]
-0.02
[-2.42; 2.43]
Varicella
(≥ 5 gpELISA units/ml)
336 297 (88.4)
[84.5; 91.6]
345 295 (85.5)
[81.3; 89.0]
2.93
[-2.18; 8.06]
(IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route; ELISA, 
enzyme-linked immunosorbent assay; Ab, antibody; gpELISA, glycoprotein antigen-based enzyme-linked immunosorbent assay.)
1Number of vaccinated subjects
2Number of subjects initially seronegative to measles (<255 mIU/ml), mumps (<10 ELISA Ab units/ml), rubella (<10 IU/ml) or varicella (<1.25 
gpELISA units/ml) contributing to each per-protocol set
3Stratified by region
4Number and percentage of subjects
Table 4: Geometric mean concentrations (GMC) of measles, mumps, rubella and varicella antibodies at 42 days post-vaccination for 
children initially seronegative to measles, mumps, rubella or varicella in the antigen-specific per-protocol sets
IM Group
N = 3741
SC Group
N = 3781
n2 GMC [95% CI] n2 GMC [95% CI]
Measles (mIU/ml) 349 2396.4 [2117.7; 2711.8] 363 2560.6 [2278.5; 2877.7]
Mumps (ELISA Ab units/ml) 349 86.4 [78.7; 95.0] 363 89.8 [82.6; 97.6]
Rubella (IU/ml) 321 97.2 [88.6; 106.7] 318 94.4 [85.7; 104.0]
Varicella (gpELISA units/ml) 333 9.8 [9.2; 10.5] 345 9.2 [8.6; 9.8]
(IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route; ELISA, 
enzyme-linked immunosorbent assay; Ab, antibody, gpELISA, glycoprotein antigen-based enzyme-linked immunosorbent assay.)
1Number of vaccinated subjects
2Number of subjects initially seronegative to measles, mumps, rubella or varicella contributing to each per-protocol setBMC Medicine 2009, 7:16 http://www.biomedcentral.com/1741-7015/7/16
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trend for lower rates of erythema and swelling was
observed on days 5 to 42 for both vaccines in the IM group
(M-M-RvaxPro: erythema 0.3% and swelling 0% in the IM
group compared with erythema 4.3% and swelling 1.6%
in the SC group; VARIVAX: erythema 4.8% and swelling
1.6% in the IM group compared with erythema 12.2%
and swelling 5.3% in the SC group).
The incidences of measles- and rubella-like rashes and of
mumps-like symptoms were similar in both groups (Table
6). Generalised varicella-like rashes were reported less fre-
quently in the IM group compared with the SC group. The
proportions of children who experienced a maximal rectal
temperature of 39.4°C or above between days 0 and 42
were comparable for the two groups: 20.9% (78/373) in
the IM group and 22.5% (84/374) in the SC group. Ele-
vated rectal temperatures occurred mainly between days 5
and 12 in both groups.
Reverse cumulative distribution curve of antibody concentrations for (a) measles, (b) mumps, (c) rubella and (d) varicella at 42  days post-vaccination for children initially seronegative to measles, mumps, rubella or varicella in the antigen-specific per-pro- tocol sets Figure 1
Reverse cumulative distribution curve of antibody concentrations for (a) measles, (b) mumps, (c) rubella and 
(d) varicella at 42 days post-vaccination for children initially seronegative to measles, mumps, rubella or vari-
cella in the antigen-specific per-protocol sets. (IM group, both vaccines administered by the intramuscular route; SC 
group, both vaccines administered by the subcutaneous route).
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Five children experienced a serious adverse event (one in
the IM group and four in the SC group). One of these
events – otitis media of moderate intensity reported for a
child at day 5 post vaccination in the SC group – was
assessed by the investigator as possibly related to both
vaccines.
Discussion
This European multicentre study has demonstrated that
concomitant IM administration of M-M-RvaxPro and
VARIVAX elicits an immune response that is comparable
with that following SC administration with respect to
response rates to measles, mumps, rubella and varicella at
42 days post vaccination. Comparable antibody concen-
trations were observed for each vaccine, whether given by
the IM or the SC route. Both vaccines were generally well-
tolerated and the safety profile for both injection routes
was also globally comparable.
Immunogenicity results for the FAS were comparable with
those for each antigen-specific PPS, indicating that both
vaccines are likely to be effective when administered by
either route in routine clinical practice. The response rates
to M-M-RvaxPro in this study were comparable with those
reported previously, and the levels of immunogenicity
observed were consistent with the antibody concentra-
tions known to provide protection against measles,
mumps and rubella. Similarly, response rates to VARIVAX
were within the expected range, regardless of the route of
administration, and were consistent with those reported
previously from a comparative study of the IM versus SC
administration of the Oka/Merck vaccine in healthy chil-
dren in the USA [41].
Although the trial was limited by being open label, details
of the administration route were sealed in an envelope
after the vaccines had been administered to reduce possi-
ble investigator bias during the second study visit. In addi-
tion, the randomisation was performed using an
interactive voice response system, thus minimising any
subject selection bias. Consistent with other vaccine trials,
the reporting of injection-site reactions and systemic
adverse events, other than erythema, swelling and pain
from days 0 to 4 post-injection, was spontaneous (that is,
not solicited). It is notable that the present study had an
excellent completion rate. All randomised children were
Table 5: Number and percentage of children with a solicited injection-site reaction on days 0 to 4 in the safety set
M-M-RvaxPro VARIVAX
IM group
N = 3741
SC group
N = 3761
IM group
N = 3741
SC group
N = 3761
Number of subjects (%)2
Solicited injection-site reaction 58 (15.5) 81 (21.5) 57 (15.2) 85 (22.6)
Erythema 39 (10.4) 61 (16.2) 33 (8.8) 63 (16.8)
Pain 26 (7.0) 27 (7.2) 26 (7.0) 32 (8.5)
Swelling 7 (1.9) 20 (5.3) 12 (3.2) 18 (4.8)
(IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route.)
1Number of vaccinated subjects according to the protocol and the actual route of administration
2 Number (and percentage) of subjects presenting the reaction at least once
Table 6: Number and percentage of children with a systemic 
adverse event on days 0 and 42 in the safety set
IM group
N = 3741
SC group
N = 3761
Number of subjects (%)2
Systemic adverse event 295 (78.9) 295 (78.5)
Vaccine-related systemic adverse event 156 (41.7) 156 (41.5)
Related to M-M-RvaxPro 153 (40.9) 149 (39.6)
Related to VARIVAX 121 (32.4) 125 (33.2)
Measles-like rash3 11 (2.9) 10 (2.7)
Mumps-like illness 0 1 (0.3)
Rubella-like rash3 10 (2.7) 10 (2.7)
Varicella-like rash3 2 (0.5) 12 (3.2)
(IM group, both vaccines administered by the intramuscular route; SC 
group, both vaccines administered by the subcutaneous route)
1Number of vaccinated subjects according to the protocol and the 
actual route of administration
2 Number (and percentage) of subjects presenting the event at least 
once
3Non-injection site rashBMC Medicine 2009, 7:16 http://www.biomedcentral.com/1741-7015/7/16
Page 9 of 11
(page number not for citation purposes)
vaccinated and only two could not be included in the
safety analysis.
The safety profile of concomitant M-M-RvaxPro and VAR-
IVAX administration in this study was consistent with that
expected from previous studies of the two vaccines, with
the most common adverse events being injection-site
reactions [41,42]. The overall tolerability profile of the
two vaccines was comparable for the IM and SC routes of
administration. As expected, however, there was a trend
for lower rates of injection-site reactions following IM
administration. Generalised varicella-like rashes were also
observed less frequently when VARIVAX was administered
by the IM route, as has been reported previously [41].
Use of the IM route for paediatric vaccinations is common
practice in Europe. As recommendations and physician
preferences vary, there is a need for greater flexibility in
routes of vaccine administration. The present study has
shown that the immunogenicities of M-M-RvaxPro and
VARIVAX administered concomitantly by the IM route are
comparable with the immunogenicities of both vaccines
administered by the SC route. The better tolerability of
both vaccines when administered by the IM route may
help to improve compliance with vaccination schedules.
This is particularly important for ensuring that children
receive a second MMR dose (as recommended in most
countries), because coverage is currently sub-optimal
[13].
These data have been used to apply successfully for mod-
ification to the licence for both M-M-RvaxPro and VAR-
IVAX, so that both SC and IM administration is now
possible.
Conclusion
The immunogenicity of M-M-RvaxPro and VARIVAX
administered by the IM route was comparable with that
for the two vaccines administered by the SC route. In addi-
tion, the globally comparable tolerability of both vac-
cines, regardless of the administration route, may help to
improve compliance with vaccination schedules as flexi-
bility in the route of administration is now possible for
both vaccines. This allows physicians to exercise their per-
sonal preference in routine practice and would be consist-
ent with common practice in many parts of Europe. This
should help to increase vaccine coverage, leading to
improved protection and reduced incidence of measles,
mumps, rubella and varicella in Europe.
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